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Autologous mesenchymal stem cells for the treatment of 
secondary progressive multiple sclerosis: an open-label 
phase 2a proof-of-concept study
Peter Connick,* Madhan Kolappan,* Charles Crawley, Daniel J Webber, Rickie Patani, Andrew W Michell, Ming-Qing Du, Shi-Lu Luan, 
Daniel R Altmann, Alan J Thompson, Alastair Compston, Michael A Scott, David H Miller, Siddharthan Chandran
Summary
Background More than half of patients with multiple sclerosis have progressive disease characterised by accumulating 
disability. The absence of treatments for progressive multiple sclerosis represents a major unmet clinical need. On 
the basis of evidence that mesenchymal stem cells have a beneﬁ cial eﬀ ect in acute and chronic animal models of 
multiple sclerosis, we aimed to assess the safety and eﬃ  cacy of these cells as a potential neuroprotective treatment for 
secondary progressive multiple sclerosis.
Methods Patients with secondary progressive multiple sclerosis involving the visual pathways (expanded disability 
status score 5·5–6·5) were recruited from the East Anglia and north London regions of the UK. Participants received 
intravenous infusion of autologous bone-marrow-derived mesenchymal stem cells in this open-label study. Our 
primary objective was to assess feasibility and safety; we compared adverse events from up to 20 months before 
treatment until up to 10 months after the infusion. As a secondary objective, we chose eﬃ  cacy outcomes to assess the 
anterior visual pathway as a model of wider disease. Masked endpoint analyses was used for electrophysiological and 
selected imaging outcomes. We used piecewise linear mixed models to assess the change in gradients over time at the 
point of intervention. This trial is registered with ClinicalTrials.gov, number NCT00395200.
Findings We isolated, expanded, characterised, and administered mesenchymal stem cells in ten patients. The mean 
dose was 1·6×10⁶ cells per kg bodyweight (range 1·1–2·0). One patient developed a transient rash shortly after 
treatment; two patients had self-limiting bacterial infections 3–4 weeks after treatment. We did not identify any 
serious adverse events. We noted improvement after treatment in visual acuity (diﬀ erence in monthly rates of change 
–0·02 logMAR units, 95% CI –0·03 to –0·01; p=0·003) and visual evoked response latency (–1·33 ms, –2·44 to –0·21; 
p=0·020), with an increase in optic nerve area (diﬀ erence in monthly rates of change 0·13 mm², 0·04 to 0·22; 
p=0·006). We did not identify any signiﬁ cant eﬀ ects on colour vision, visual ﬁ elds, macular volume, retinal nerve 
ﬁ bre layer thickness, or optic nerve magnetisation transfer ratio.
Interpretation Autologous mesenchymal stem cells were safely given to patients with secondary progressive multiple 
sclerosis in our study. The evidence of structural, functional, and physiological improvement after treatment in some 
visual endpoints is suggestive of neuroprotection.
Funding Medical Research Council, Multiple Sclerosis Society of Great Britain and Northern Ireland, Evelyn Trust, 
NHS National Institute for Health Research, Cambridge and UCLH Biomedical Research Centres, Wellcome Trust, 
Raymond and Beverly Sackler Foundation, and Sir David and Isobel Walker Trust.
Introduction
Multiple sclerosis (MS) aﬀ ects more than 2 million people 
worldwide and is the most common non-traumatic cause 
of disability in young (<50 years) European adults.1 It is a 
multifocal CNS disorder that has two distinct clinical phases 
corresponding to inter-related pathological processes: focal 
inﬂ ammation that drives activity during the relapse-remitting 
stage and neuro degeneration that underlies progressive 
disease char acterised by accumulating ﬁ xed disability.2 
Although important advances in treatment to reduce 
relapse rate have been made in the past two decades,3,4 no 
treatments are available for the roughly half of patients 
with MS who have progressive disease.5 There is therefore 
a great and unmet clinical need for the development of 
neuroprotective treatments.
Multipotent mesenchymal stromal cells are bone-
marrow cells that can be expanded ex vivo and will readily 
diﬀ erentiate into mesodermal cell derivatives.6 In addition 
to tissue engineering applications that target the repair of 
skeletal tissue defects,7 biological properties independent 
of diﬀ erentiation suggest that mesenchymal stem cells 
could have a therapeutic role through strategies other 
than tissue replacement in diseases such as MS.8 These 
strategies include neuroprotection through paracrine 
eﬀ ects on the CNS microenvironment, augmentation of 
endogenous axonal and myelin repair processes, and 
immune regulatory activity.8,9 Increasing evidence shows 
both neuroprotection and functional improvement after 
infusion with mesenchymal stem cells in mouse models 
of relapsing-remitting and chronic MS.10–14
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Clinically, mesenchymal stem cells have been used in 
the treatment of immune-mediated human diseases 
including steroid-resistant graft-versus-host disease and 
systemic lupus erythematosus.15–17 Three recent reports 
have also described the use of intrathecally delivered 
autologous mesenchymal stem cells in MS without adverse 
events or signiﬁ cant changes in general clinical outcomes 
(webappendix).18–20 However, assessment of neuroprotection 
in the context of MS is challenging because of clinical and 
pathological heterogeneity.21 To increase sensitivity for 
structural and functional treat ment eﬀ ects, the use of 
eligibility criteria that select cohorts with speciﬁ c and 
clinically eloquent lesions, such as those of the anterior 
visual pathway, enables assess ment of tailored and detailed 
outcomes.22,23 By use of this approach, we aimed to compare 
safety and eﬃ  cacy outcomes for patients with secondary 
progressive MS before and after intravenous treatment 
with autologous mesenchymal stem cells.
Methods
Participants
Between November, 2007, and August, 2010, we did an 
open-label phase 2a proof-of-concept study involving 
participants recruited from the East Anglia and north 
London regions of the UK (identiﬁ ed from MS and 
general neurology clinics). We screened patients for 
eligibility between November, 2007, and June, 2009. 
Eligible participants were those aged 18–65 years with 
clinically deﬁ nite MS according to the Poser criteria,24 
an expanded disability status scale (EDSS) score of 
2·0–6·5, clinical evidence of optic nerve involvement 
(deﬁ ned as a history of optic neuritis, Uhthoﬀ ’s 
phenomenon, or optic atrophy on examination), 
abnormal visual evoked potentials from one or both 
eyes consistent with de myelination, a retinal nerve ﬁ bre 
layer thickness of at least 45 μm in one eye, a T2 lesion 
on MRI of the optic nerve (webappendix), and the 
capacity to give consent. Patients were excluded if they 
had a bleeding disorder, had received interferon beta or 
glatiramer acetate within 6 months of trial entry, or had 
previously used other disease modifying therapies at 
any point. All patients gave written informed consent 
before study entry and approval was obtained from the 
local ethics committee (Cambridgeshire 2 regional 
ethics committee).
Procedures
We generated clinical-grade mesenchymal stem cells 
under good manufacturing practice conditions with 
standard operating procedures.15 Brieﬂ y, we separated 
bone-marrow mononuclear cells by density gradient 
centrifugation in Ficoll-Paque Premium (GE Healthcare 
UK Ltd, Buckinghamshire, UK). We resuspended the 
washed cells in phosphate-buﬀ ered saline/EDTA (Miltenyi 
Biotec Ltd, Surrey, UK) and cultured them in Dulbecco’s 
modiﬁ ed Eagle’s medium (low glucose; Invitrogen, 
Paisley, UK) supplemented with 10% fetal bovine serum 
(Hyclone; Perbio Science, Northumberland, UK), plated at 
a density of 1×10⁸ cells per cell factory (Nunc, Thermo 
Scientiﬁ c, Northumberland, UK). Near conﬂ uent cultures 
(>80%) were treated with 0·25% trypsin-EDTA (Invitrogen) 
and replated at 3·5×10⁶ cells per cell factory. Mesenchymal 
stem cells were harvested and cryopreserved in 4·5% 
human albumin solution (Bio Products Laboratory, 
Hertfordshire, UK) with di methyl sulphoxide (Origen 
Biomedical Inc, Helsingborg, Sweden) at a ﬁ nal 
concentration of 10%. Mesenchymal stem cells were then 
characterised in accordance with International Society of 
Cellular Therapy recommen dations.25 Brieﬂ y, this included 
evidence of trilineage diﬀ erentiation potential (adipocyte, 
chondrocyte, osteocyte) and ﬂ ow cytometry to conﬁ rm 
expression of CD73, CD90, and CD105 surface molecules 
(>95%) and absence of CD34, CD45, CD14, and CD3 
(<2%). Release criteria for clinical use included absence of 
contamination by pathogens (as documented by aerobic 
and anaerobic cultures and mycoplasma testing), and lack 
of any genomic copy number changes as assessed with 
1-Mb-resolution bacterial artiﬁ cial chromosome array 
comparative genomic hybridisation.26
We administered autologous mesenchymal stem cells 
intravenously to patients with secondary progressive MS. 
Administration of the cells was done as a day-case 
procedure. To reduce type I hypersensitivity reactions, 
premedication with 10 mg chlor pheniramine, 100 mg 
hydrocortisone, and 10 mg metoclopramide was given 
30 min before administration of the cells. Cryo preserved 
cells were thawed (≤4 min) and im mediately infused over 
15 min through a peripheral venous cannula. After 
administration of cell suspensions, we infused normal 
saline (500 mL) over 4 h.
Our primary objective was to assess feasibility and safety; 
our secondary objectives were to assess eﬃ  cacy on clinical, 
electrophysiological, and structural outcomes, in addition 
to providing information on the mechanism of any 
recorded eﬀ ect. We used a sentinel lesion approach based 
on the diseased anterior visual pathway to increase power 
to detect treatment eﬀ ects,23 and we used a pretest–post-
test design to compare adverse events and eﬃ  cacy 
measures before and after the intervention. We assessed 
participants at 3–6 month intervals for at least 12 months 
before and 6 months after treatment (webappendix). 
Assessment at each timepoint was split into two visits with 
a gap of less than 2 weeks; clinical assessment and visual 
evoked responses were done in Cambridge, UK, and MRI, 
optical coherence tomography, and neuro-ophthal-
mological assessments were done at the University College 
London Institute of Neurology (London, UK). Clinical 
assessment involved neurological and medical history with 
recording of adverse events and scores on the EDSS, MS 
functional composite (MSFC), Addenbrooke’s cognitive 
examination revised, 29-item MS impact scale, and Beck 
depression inventory II. Whole and central ﬁ eld 
checkerboard pattern-reversal visual evoked responses 
were recorded with reversal achromatic checks subtending 
See Online for webappendix
Articles
152 www.thelancet.com/neurology   Vol 11   February 2012
60´ at the eye. Neuro-opthalmological assessment included 
visual acuity with a retroilluminated early treatment 
diabetic retinopathy study chart, contrast acuity with 
retroilluminated Sloan charts, colour vision with the 
Farnsworth–Munsell 100-hue test, and visual ﬁ eld 
assessment by automated static perimetry (Humphrey 
ﬁ eld analyser, 30-2 protocol). Optical coherence tomography 
images were acquired by a single operator (MK) with a 
time domain optical coherence tomograph (Stratus OCT 
Model 3000; Carl Zeiss Meditec, Dublin, CA, USA).23
MRI images were acquired with a Magnetom 3·0 T 
Tim Trio scanner (Siemens, Erlangen, Germany) with a 
12-element receiver head coil. Several MRI-based 
measures were assessed: optic nerve cross-sectional area; 
optic nerve diﬀ usion tensor imaging measures of 
fractional anisotropy, mean diﬀ usivity, axial diﬀ usivity, 
and radial diﬀ usivity; optic nerve magnetisation 
transfer ratio; whole-brain T2 lesion volume; whole-brain 
T1 hypointense lesion volume; whole-brain magnetisa-
tion transfer ratio; brain T1 hypointense lesion 
magnetisation transfer ratio; and brain T2 lesion 
magnetisation transfer ratio.23 Intersessional stability of 
imaging measures was conﬁ rmed by contemporary 
assessment of ten locally recruited healthy volunteers.
Visual evoked responses, optic nerve area, optic nerve 
magnetisation transfer ratio, and optic nerve diﬀ usion 
tensor imaging based outcomes were assessed by a 
single observer (MK) from whom participant status 
(before or after treatment) was masked. Lesional analysis 
was done after image acquisition at each visit. Brain 
volume and whole-brain magnetisation transfer ratio 
were done with automated methods with minimal 
manual corrections.
Statistical analysis
We used piecewise linear mixed models to assess,27 for a 
given measure, the change in gradient over time at the 
point of intervention; the given measure was the response 
variable, with the time from intervention and the time 
multiplied by an after-intervention interaction term as 
the two predictors. Such models allow estimation of the 
gradients before and after intervention, and of the 
gradient change with its statistical signiﬁ cance. For 
analyses of data involving separate values for each eye 
over time, we added an additional level to the model with 
individual eyes as levels within participants. For the 
EDSS score, although the before and after gradients were 
estimated as above, the test of gradient change used the 
non-parametric Wilcoxon sign rank test to compare the 
two ratios: change in EDSS score before or time interval 
before versus change in score after or time interval after. 
There was no evidence of deviation from model 
assumptions. In particular there was no evidence for 
non-normality or heteroscedasticity of residuals, or 
evidence against linearity assumptions. All of the 
reported mixed models achieved convergence with 
estimates for both the variance components and the ﬁ xed 
eﬀ ects. Unrecordable visual evoked responses, related to 
severe dysfunction due to disease, were represented by 
amplitude values of 0 μV and latency values of 180 ms 
(the maximum recorded during our study). Analyses 
were done with Stata SE (versions 9.2 and 11). Power 
calculations could not be done before the study because 
of the lack of information from previous studies on 
potential eﬀ ect sizes. This trial is registered with 
ClinicalTrials.gov, number NCT00395200.
Role of the funding source
The sponsors of the study had no role in study design, 
data collection, data analysis, data interpretation, or 
writing of the report. The corresponding author had full 
access to all the data in the study and had ﬁ nal 
responsibility for the decision to submit for publication.
Results
Figure 1 shows the study proﬁ le and table 1 the 
participants’ characteristics. All participants had 
secondary progressive MS,28 with clinical and electro-
physiological evidence of optic nerve involvement. In 
the 2–26 years before recruitment, nine patients had 
clinical optic neuritis (three bilateral) and one had 
98 patients assessed for eligibility
84 ineligible
14 eligible
3 declined to participate
11 participants recruited
1 withdrew consent
10 underwent bone-marrow aspiration, had mesenchymal stem 
      cells cultured to target dose and cryopreserved, and were 
      treated with the cells
Figure 1: Study proﬁ le
Measure at recruitment
Number of participants 10
Sex ratio (men:women) 7:3
Age (years) 48·8 (4·1; 40–53)
Duration of multiple sclerosis (years) 14·4 (7·9; 5–26)
Expanded disability status score 6·1 (0·3; 5·5–6·5)
Time since last clinical episode of optic neuritis 
(years)*
11·9 (8·2; 2–26)
Data are n or mean (SD; range). *Nine participants. 
Table 1: Participants’ characteristics
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Uhthoﬀ ’s phenomenon. Two patients described a single 
clinical relapse event in the pretreatment phase, neither 
of which involved the anterior visual pathway. One 
patient had been previously treated with disease 
modifying therapy (interferon beta for 1 year, with 
treatment discontinued owing to disease progression 
2 years before recruitment into our trial). 
We successfully isolated and cultured mesenchymal 
stem cells to the target dose from all bone-marrow aspirates 
(mean total cultured dose 2·0×10⁶ cells per kg, range 
1·1×10⁶–3·7×10⁶). Mean culture duration was 24 days 
(20–30). Patients received a single infusion of autologous 
cells after monitoring for a mean of 17·3 months 
(14·1–20·9) during the pretreatment phase. The mean 
administered dose was 1·6×10⁶ cells per kg bodyweight 
(1·1×10⁶–2·0×10⁶); mean volume of cell suspensions was 
167·2 mL (range 89–246). We did not record any adverse 
events during infusion. One patient developed a macular 
rash over the anterior chest at about 3 h after the start of 
infusion that resolved spontaneously over 12 h; a further 
patient described scalp pruritus beginning 1 week after 
treatment and resolving spontaneously 2 weeks later. Two 
patients had infections: a self-limiting upper-respiratory 
tract infection 3 weeks after infusion (not requiring 
treatment) and an Escherichia coli urinary-tract infection 
4 weeks after infusion (treated with oral antibiotics). 
Results of weekly blood testing of clinical chemistry, 
haematology, and immunology during the 4 weeks after 
infusion was unremarkable. Compared with pre treatment 
titres, no changes were evident in the post-treatment 
period for T-cell subset counts (CD3, CD4, CD8, CD19, and 
CD56) or humoral immunity assessed by titres to common 
antigens (mumps, measles, rubella, varicella zoster, 
tetanus, Haemophilus inﬂ uenzae type B, and pneumo coccal 
antigens 1, 3, 4, 5, 6B, 7F, 8, 14, 18C, 19A, 19F, and 23F). We 
did not identify any delayed adverse events during the post-
treatment phase (mean 7·0 months, 5·8–10·2).
After treatment, there was an improvement in log of 
minimum angle of resolution (logMAR) visual acuity 
(ﬁ gure 2, table 2) and low contrast visual acuity (table 2, 
webappendix). No signiﬁ cant changes were evident in 
colour vision or visual ﬁ elds. Physiological measures 
showed a post-treatment reduction in visual evoked 
response latency and an increase in visual evoked response 
amplitude; imaging measures showed an increase in optic 
nerve area after treatment (ﬁ gure 2, table 2). No change 
was evident in macular volume, retinal nerve ﬁ bre layer 
thickness, or optic nerve magnetisation transfer ratio.
There was reduction after treatment in general disability 
progression measured by EDSS (table 2). We did not 
identify a change in the MSFC or in measures of 
depression, cognition, and self-reported eﬀ ect of MS on 
daily living. T1 hypointense lesion volume decreased after 
treatment and magnetisation transfer ratio increased, but 
these changes were not statistically signiﬁ cant. We did 
not identify any changes in the rate of T2 lesion 
accumulation or general brain atrophy after treatment.
Discussion
Our proof-of-concept study provides evidence that an 
intervention might aﬀ ect the disease course in pro-
gressive MS. Speciﬁ cally, we show that after intravenous 
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Figure 2: Change in visual function, visual evoked response amplitude, and 
optic nerve area
Paired monthly estimated rates of change in log of minimum angle of 
resolution (logMAR) visual acuity, whole-ﬁ eld visual evoked response latency, 
and optic nerve area are shown for individual patients before and after 
treatment connected by solid lines. Pretreatment and post-treatment mean 
rates of change are also shown connected with a dashed line. Signiﬁ cance 
tests are shown for a diﬀ erence between mean rates of change before and 
after treatment.
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administration of autologous mesenchymal stem cells, 
patients with secondary progressive disease improved on 
measures of visual function, physiology, and structure 
without evidence of signiﬁ cant adverse events. Improve-
ments in visual acuity and contrast sensitivity after 
treatment were accompanied by changes in masked 
outcome measures, as a reduction in visual evoked 
response latency, increase in visual evoked response 
amplitude, and an increase in optic nerve area. General 
disability progression measured by EDSS was also 
reduced after treatment.
Despite recent major advances in immunomodulatory 
therapies, there are no treatments to slow, stop, or 
reverse the accumulation of ﬁ xed disability in secondary 
progressive MS. This relates in part to the complex and 
incompletely understood biology of progression. 
Further more, assessing neuroprotective therapies in 
MS presents a substantial challenge because of the 
variability in disease features and course, combined 
with insensitivity of generic clinical outcomes. We 
therefore adopted a sentinel lesion approach based on 
a detailed assessment of the anterior visual pathway as 
a model of wider processes. We chose the anterior 
visual pathway because of convergence of reliable and 
validated outcomes for clinical function, physiology, 
and structure.22 Nevertheless, because of wide variation 
between individuals in the rate of disease progression, 
a further challenge in testing advanced therapies such 
as cell-based interventions is to design early stage trials 
that achieve adequate power. On this basis, we used a 
pretest–post-test design to increase eﬀ ect size and 
therefore increase statistical power by 40–80%.23 The 
limitations of this approach are that change evident 
after treatment cannot be attributed exclusively to the 
eﬀ ects of treatment since factors we did not record 
might also contribute. Changes identiﬁ ed after 
treatment therefore need to be conﬁ rmed as treatment 
eﬀ ects by replication in trials with random allocation 
between comparator groups. Such trials require 
substantial investment, and feasibility, safety, and 
eﬀ ect-size-deﬁ ning studies such as ours therefore have 
a key role in informing decisions about whether further 
studies are justiﬁ able and how they should be designed. 
Further limitations of our study include the small 
cohort size and lack of masking for clinical outcomes. 
There is also risk of type I error due to multiple 
statistical comparisons; our results should therefore be 
regarded as hypothesis generating and will need 
conﬁ rmation in future studies. Nevertheless, inter-
pretation of post-treatment changes is aided by masked 
electrophysiological and imaging outcomes that are 
probably resistant to observer bias or placebo eﬀ ects. 
Moreover, unlike designs in which treatment is 
started immediately after recruitment, post-treatment 
change in our study is robust to regression to the mean 
because of our prolonged pre treatment assessment 
phase.
We do not know the precise mechanism by which 
mesenchymal stem cells might act in our study. 
However, the ﬁ ndings from our masked analyses 
showed an increase in optic nerve area and reduction in 
visual evoked response latency that are consistent with 
a neuroprotective eﬀ ect because of the promotion of 
myelin repair. Our ﬁ ndings of a possible reduction in 
brain T1 hypointense lesion volume and an increase in 
brain T1 lesion magnetisation transfer ratio provide 
indirect support for this idea.29,30 Remyelination is the 
regenerative process by which myelin sheaths are 
restored to demyelinated axons and the failure of 
remyelination is implicated in the neuronal and axonal 
loss that underlies progressive disability.31 Although our 
study was not designed speciﬁ cally to address the eﬀ ects 
of intervention on inﬂ ammatory MRI metrics, we did 
Rate of change Diﬀ erence in rate of change 
after treatment (95% CI)
p value
Before 
treatment
After 
treatment
Vision
Visual acuity (logMAR) 0·0050 –0·0207 –0·0205 (–0·0325 to –0·0085) 0·003
25% contrast acuity (logMAR) 0·0022 –0·0207 –0·0202 (–0·0330 to –0·0073) 0·011
5% contrast acuity (logMAR) 0·0083 –0·0372 –0·0371 (–0·0560 to –0·0181) 0·001
1·25% contrast acuity (logMAR) 0·0063 –0·0370 –0·0369 (–0·0552 to –0·0185) 0·001
Colour vision (Farnsworth–Munsell 
100-hue test √total error score)
0·1017 –0·0975 –0·1011 (–0·2567 to 0·0544) 0·070
Visual ﬁ eld (mean deviance) 0·0395 0·00311 0·0192 (–0·1062 to 0·1445) 0·893
Full ﬁ eld visual evoked response 
latency (ms)
0·4843 –0·8438 –1·3280 (–2·4447 to –0·2114) 0·020
Full ﬁ eld visual evoked response 
amplitude (μV)
–0·1084 0·1503 0·2587 (0·0705 to 0·4469) 0·007
Macular volume (mm³) 0·0002 0·0041 0·0040 (–0·0135 to 0·0214) 0·654
Retinal nerve ﬁ bre layer thickness 
(μm)
–0·0052 0·0474 0·0527 (–0·3533 to 0·4586) 0·799
Optic nerve area (mm²) –0·0216 0·1046 0·1262 (0·0368 to 0·2155) 0·006
Optic nerve magnetisation transfer 
ratio (pu)
0·0656 0·0529 0·0529 (–0·1271 to 0·2328) 0·565
General
Expanded disability status scale 0·0257 –0·0012 –0·0269 (–0·0431 to –0·0107) 0·028
Multiple sclerosis functional 
composite (Z score)
–0·0217 0·0141 0·0359 (–0·0275 to 0·0992) 0·267
Addenbrooke’s cognitive 
examination (revised)
0·0492 0·2690 0·2198 (–0·1343 to 0·5739) 0·224
29-item multiple sclerosis impact 
scale
–0·3710 –0·5152 –0·1443 (–2·0865 to 1·7979) 0·884
Beck depression inventory II 0·0965 –0·2663 –0·3628 (–0·9378 to 0·2121) 0·216
T1 lesion volume (mm³) 204·35 –60·73 –265·08 (–574·85 to 44·69) 0·094
T1 lesion magnetisation transfer 
ratio (pu)
–0·1867 0·5791 0·7659 (–0·1389 to 1·6706) 0·097
T2 lesion volume (mm³) 155·89 20·90 –134·98 (–579·64 to 309·67) 0·552
T2 lesion magnetisation transfer 
ratio (pu)
–0·1738 0·3859 0·5597 (–0·2703 to 1·3896) 0·186
Total brain volume (%) –0·0880 –0·1470 –0·0590 (–0·1434 to 0·0254) 0·171
Data are units per month unless otherwise stated. MAR=minimum angle of resolution. pu=percent units.
Table 2: Eﬃ  cacy outcomes
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not identify any change in the rate of T2 lesion 
accumulation after treatment. Similarly, the lack of 
eﬀ ect on optical coherence tomography measures after 
treatment supports a view that structural change in 
unmyelinated axons was not a signiﬁ cant factor. The 
lack of signiﬁ cant change in optic nerve magnetisation 
transfer ratio measures suggests that the clinical and 
neuro physiological improvements might relate to 
diﬀ use tissue repair in the diseased anterior visual 
pathways or to our small study size and technical 
limitations, in view of the restricted previous experience 
of optic nerve magnetisation transfer ratio at 3 T. Taken 
together our ﬁ ndings are consistent with a growing 
body of published work in acute and chronic models of 
MS showing neuroprotective eﬀ ects of mesenchymal 
stem cells independent of directed diﬀ erentiation or 
cell replacement (panel).8,9 Central or peripheral 
mechanisms that might explain these results include 
immuno regulation, and modiﬁ cation of the cellular 
environment causing trophic or anti-inﬂ ammatory 
eﬀ ects. Further more, recent studies suggest that 
mesenchymal stem cells can promote the endogenous 
CNS repair processes of oligo dendrogenesis and 
remyelination,32,33 raising the possibility that re-
myelination underlies the evidence for neuroprotection 
in our study.
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Panel: Research in context
Systematic review
We searched Medline (1950 to August, 2011), Embase 
(1980 to August, 2011), and the Cochrane Central Register of 
Controlled Trials (The Cochrane Library issue 4, 2011) with 
the terms “multiple sclerosis” and “mesenchymal stem cells” 
for clinical trials published up to August, 2011, that report the 
eﬀ ect of mesenchymal stem cells on the rate of disease 
progression in secondary progressive multiple sclerosis. We 
did not limit our search by language. We identiﬁ ed three 
published trials in which autologous ex-vivo expanded 
mesenchymal stem cells were administered intrathecally,18 
intrathecally and intracisternally,19 or intrathecally and 
intravenously (webappendix).20
Interpretation
Consistent with previous studies, our ﬁ ndings show that 
intravenous administration of autologous mesenchymal 
stem cells to patients with secondary progressive multiple 
sclerosis is feasible and safe. Our ﬁ ndings also suggest 
structural, functional, and physiological improvement after 
treatment consistent with neuroprotection.
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